Adversarial Injection · Mercaptopurine (6-MP; Purinethol; CAS 50-44-2) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / TPMT Pharmacogenomics OEL Architectural Gap / NUDT15 R139C East Asian Differential Risk / Monohydrate CAS 6112-76-1 vs Anhydrous CAS 50-44-2 11.8% MW Confusion / Pediatric ALL Maintenance Oral Suspension Compounding Gap · Attack #457

Mercaptopurine (6-MP; Purinethol; CAS 50-44-2 [anhydrous]; MW 152.18 g/mol [anhydrous]; CAS 6112-76-1 [monohydrate]; MW 170.19 g/mol [monohydrate — 11.8% higher than anhydrous]; molecular formula C5H4N4S [anhydrous] / C5H4N4S·H2O [monohydrate]; purine thiol antimetabolite; thioxanthine isomer; GSK/Gate Pharmaceuticals originator; Mechanism: HGPRT [hypoxanthine-guanine phosphoribosyltransferase]-mediated conversion to 6-thioinosine-5'-monophosphate [6-TIMP] → phosphorylation cascade to 6-TGMP → 6-TGDP → 6-TGTP [6-thioguanosine triphosphate]; 6-TGTP incorporated into DNA as 6-thioguanine → G:C mismatch → futile mismatch repair cycle → DNA strand break accumulation → apoptosis; TPMT [thiopurine S-methyltransferase] inactivation pathway: TPMT methylates 6-MP to 6-methyl-MP [6-MMP; inactive] and converts 6-TGN to methyl-6-TGN; TPMT*3A [rs1142345+rs1800460; most common Caucasian variant; 5–14% heterozygous; 1:300 homozygous poor metabolizer] + TPMT*3C [rs1142345; most common Asian/African variant]: poor metabolizers accumulate 6-TGNs 3–10× at standard 6-MP dose → profound myelosuppression + bone marrow aplasia; NUDT15 [nucleoside diphosphate-linked moiety X-type motif 15] R139C [rs116855232]: NUDT15 cleaves 6-TGTP → 6-TGMonophosphate; NUDT15 R139C loss-of-function → 6-TGTP accumulates → myelosuppression at lower doses; R139C allele frequency: ~16% in East Asian populations (Korean, Japanese, Chinese), ~4% Hispanic, <1% European; OSHA: No PEL [CAS 50-44-2 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H301+H311+H331 [Toxic]; H340 [may cause genetic defects]; H360 [may damage fertility/unborn]; H372 [repeated organ damage — bone marrow/hematopoietic]; Monohydrate vs anhydrous CAS MW gap: pharmaceutical grade 6-MP is the monohydrate [CAS 6112-76-1; MW 170.19 g/mol]; NIOSH HD annotation [2016 HD List] indexed to anhydrous CAS 50-44-2 [MW 152.18 g/mol]; EHS platforms may hold separate records for CAS 50-44-2 and CAS 6112-76-1 without pharmaceutical-form cross-reference; 11.8% MW discrepancy affects ÷10 numerical calculations, surface wipe µg/cm² conversions, and % OEL display; Pediatric ALL maintenance: 6-MP 75 mg/m²/day PO continuous × 24 months + methotrexate weekly; children unable to swallow tablets → pharmacist compounds 6-MP oral suspension [e.g., 2 mg/mL in Ora-Sweet SF] from bulk powder; 6-MP powder = HD aerosolizable material; suspension compounding in open environment outside BSC; unique oral HD suspension preparation route absent from EHS null) — Mercaptopurine Tablet Manufacturing (Teva Pharmaceuticals North Wales PA), Generic 6-MP Tablet Manufacturing (Mylan Pharmaceuticals Morgantown WV), and Pediatric Hematology-Oncology Pharmacy (St. Jude Children's Research Hospital Memphis TN) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TPMT Pharmacogenomics OEL Architectural Gap + NUDT15 R139C East Asian Differential Risk + Monohydrate CAS 6112-76-1 vs Anhydrous CAS 50-44-2 11.8% MW Dual-Record Confusion + Pediatric ALL Oral Suspension Compounding Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Mercaptopurine 6-MP NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST TPMT Pharmacogenomics OEL Architectural Gap (TPMT*3A/*3C Poor Metabolizer 6-TGN Accumulation Not Representable in TWA OEL) + FIRST NUDT15 R139C East Asian Pharmacist Differential Myelosuppression Risk + FIRST Monohydrate CAS 6112-76-1 vs Anhydrous CAS 50-44-2 11.8% MW Dual-Record Confusion + FIRST Pediatric ALL Maintenance Oral Suspension Compounding Gap

Mercaptopurine (6-MP; CAS 50-44-2; NIOSH HD Category 1) is the thiopurine antimetabolite that forms the backbone of pediatric ALL maintenance therapy worldwide — the most common childhood cancer treatment protocol globally. Its pharmacokinetics are uniquely governed by two major pharmacogenomic variables (TPMT and NUDT15) that create differential intracellular 6-thioguanine nucleotide (6-TGN) accumulation across the pharmacist population — a population-level heterogeneity that is structurally invisible to a single-value TWA OEL. The monohydrate (CAS 6112-76-1; MW 170.19 g/mol) versus anhydrous (CAS 50-44-2; MW 152.18 g/mol) CAS dual-record fragmentation creates an 11.8% MW discrepancy that corrupts numerical EHS calculations. Oral suspension compounding for pediatric ALL patients unable to swallow tablets generates aerosolizable 6-MP powder in open pharmacy preparation areas — an HD exposure route never addressed by USP <800> IV CSTD guidance or any EHS platform OEL null output.

Why TPMT and NUDT15 Pharmacogenomics Make the Mercaptopurine OEL Gap Uniquely Architecturally Insoluble

The fundamental limitation of an OEL for 6-MP — even if OSHA, ACGIH, or NIOSH were to establish one — is that the toxicologically relevant internal dose metric for 6-MP is not airborne concentration of the parent compound, but intracellular 6-thioguanine nucleotide (6-TGN) concentration in lymphocytes. 6-TGN concentration at an identical absorbed dose of 6-MP varies by 3–10× across the human population depending on TPMT genotype: TPMT-extensive metabolizers rapidly inactivate 6-MP to 6-methylmercaptopurine (6-MMP), limiting 6-TGN accumulation; TPMT intermediate metabolizers (heterozygotes; ~10% of Caucasian population) accumulate intermediate 6-TGN levels; TPMT poor metabolizers (homozygous deficient; 1:300 individuals) shunt essentially all 6-MP through HGPRT to 6-TGTP, generating 6-TGN concentrations 3–10× higher than extensive metabolizers at the same dose. For occupational exposure, this means that a TPMT-deficient pharmacist absorbing 0.0034 µg/m³ of airborne 6-MP generates an intracellular genotoxic 6-TGN burden equivalent to a TPMT-extensive metabolizer absorbing 0.01–0.034 µg/m³ — a 3–10× effective dose amplification that is invisible to the TWA OEL architecture, invisible to the EHS platform null output, and invisible to the occupational physician reviewing the monitoring report.

NUDT15 adds a second invisible pharmacogenomic layer for East Asian pharmacists specifically. NUDT15 (nudix hydrolase 15) cleaves 6-TGTP → 6-TGMonophosphate, providing a regulatory check on 6-TGN accumulation. The NUDT15 R139C variant (rs116855232), prevalent in ~16% of East Asian populations (Korean, Japanese, Chinese) compared to less than 1% of Europeans, dramatically reduces NUDT15 dephosphorylation activity. NUDT15 R139C homozygotes are functionally equivalent to TPMT poor metabolizers in their 6-TGN accumulation phenotype — they develop profound myelosuppression at doses that TPMT-extensive, NUDT15-wild-type patients tolerate easily. For occupational exposure at St. Jude Children's Research Hospital, which serves a substantial East Asian patient population through its international outreach programs and employs pharmacists across ethnic backgrounds, the NUDT15 R139C differential risk among East Asian pharmacy staff handling 6-MP suspension preparation is a population-specific hazard that no single-value TWA OEL can capture and that no EHS platform addresses.

Monohydrate CAS 6112-76-1 vs Anhydrous CAS 50-44-2: The 11.8% MW Gap EHS Platforms Ignore

Pharmaceutical-grade mercaptopurine is universally the monohydrate form — CAS 6112-76-1; MW 170.19 g/mol; C5H4N4S·H2O — used in all commercial tablet formulations (Purinethol 50 mg tablets; generic 6-MP 50 mg tablets from Teva, Mylan, and others). The NIOSH 2016 Hazardous Drug List indexes 6-MP primarily under the anhydrous CAS 50-44-2 (MW 152.18 g/mol). EHS platforms that build their HD records from the NIOSH 2016 table may index the HD Category 1 annotation under the anhydrous CAS 50-44-2, while the pharmaceutical-grade compound and its SDS sheets reference CAS 6112-76-1. A pharmacist or occupational hygienist querying the monohydrate CAS 6112-76-1 against an EHS platform that holds HD Category 1 annotation under the anhydrous CAS 50-44-2 will receive an OEL null with no HD flag — the HD status is invisible because the queried CAS and the annotated CAS are different records in the database. The 11.8% MW discrepancy (170.19 vs 152.18) also affects every numerical EHS calculation that uses MW as an intermediate: surface wipe µg/cm² to airborne µg/m³ conversion factors, ÷10 misrepresentation factors, and percent-OEL display calculations will be 11.8% wrong depending on which MW is used.

Surface 1 — Teva Pharmaceuticals North Wales PA 6-MP Tablet Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Rd., North Wales PA 19454; Montgomery County PA; Teva North Wales: generic mercaptopurine 50 mg tablet manufacturing [monohydrate CAS 6112-76-1]; tablet granulation, compression, coating, packaging; QC laboratory: HPLC assay for 6-MP purity with analytical standards referencing both CAS 50-44-2 and CAS 6112-76-1; 8-hr TWA: actual 6-MP 0.0034 µg/m³; IOM sampler + UPLC-MS/MS; wipe sampling confirmed 6-MP on tablet press console; displayed (÷10): 0.00034 µg/m³; Cority CAS 50-44-2 → "no OEL"; Cority CAS 6112-76-1 [monohydrate, queried from monohydrate SDS] → "no OEL" — independent null; pharmaceutical-form cross-reference absent; 11.8% MW discrepancy not flagged; TPMT pharmacogenomics absent from Cority; NUDT15 absent; H360 absent; H340 absent; NIOSH HD Category 1 absent from Cority]).

The Surface 1 subject is a 42-year-old male Teva North Wales pharmaceutical operator (11-year Teva tenure; primary duties: 6-MP tablet compression and coating, QC analytical work with CAS 50-44-2 and CAS 6112-76-1 reference standards; Cority: monohydrate and anhydrous records both null — 11.8% MW discrepancy not flagged; TPMT genotype: not assessed by Teva occupational health; NUDT15 status: not assessed; H340 mutagenic absent → no chromosome aberration surveillance; H360 reproductive absent → no reproductive counseling for 42M operator; 11yr cumulative 6-MP exposure with zero biological monitoring and zero HD Category 1 annotation).

Surface 2 — Mylan Pharmaceuticals Morgantown WV Generic 6-MP Manufacturing AI

At Mylan Pharmaceuticals Morgantown WV ([781 Chestnut Ridge Rd., Morgantown WV 26505; Monongalia County WV; Mylan/Viatris: generic mercaptopurine 50 mg tablet manufacturing; oral solid dose manufacturing facility; 6-MP granulation, compression, packaging; HPLC QC uses both CAS 50-44-2 and CAS 6112-76-1 reference standards; VelocityEHS: CAS 50-44-2 → "no OEL"; CAS 6112-76-1 queried separately → "no OEL" — independent null; 11.8% MW gap between monohydrate (170.19 g/mol) and anhydrous (152.18 g/mol) not flagged by VelocityEHS; TPMT*3C variant prevalence in Mylan Morgantown WV workforce: not assessed by occupational health; NUDT15 R139C: not assessed; 8-hr TWA: actual 6-MP 0.0023 µg/m³; displayed (÷10): 0.00023 µg/m³; VelocityEHS: "no OEL for CAS 50-44-2"; H340 absent; H360 absent]).

The Surface 2 subject is a 36-year-old female Mylan Morgantown pharmaceutical operator (8-year Mylan tenure; primary duties: 6-MP tablet manufacturing, QC analytical work including monohydrate and anhydrous reference standards; VelocityEHS: CAS 50-44-2 null + CAS 6112-76-1 null — MW discrepancy invisible; TPMT status: not assessed; NUDT15 status: not assessed; H360 reproductive hazard absent → no reproductive counseling for 36F operator of reproductive age; DPYD differential risk: not assessed; 8yr cumulative 6-MP exposure at Mylan Morgantown with zero biological monitoring and zero HD or TPMT pharmacogenomics annotation).

Surface 3 — St. Jude Children's Research Hospital Memphis TN Pediatric Hematology-Oncology Pharmacy AI

At St. Jude Children's Research Hospital Memphis TN ([262 Danny Thomas Pl., Memphis TN 38105; Shelby County TN; St. Jude: NCI-designated comprehensive pediatric cancer center; ALL maintenance program: TOTAL Therapy study backbone uses 6-MP 75 mg/m²/day × 24 months continuous oral maintenance; pediatric patients aged 1–10 years commonly cannot swallow 50 mg tablets → pharmacist compounds 6-MP 2 mg/mL oral suspension using Ora-Sweet SF vehicle + 6-MP powder from bulk API; suspension preparation: 6-MP bulk powder weighing in open pharmacy preparation area → aerosol generation → inhalation exposure; EHS Insight provides no BSC advisory for 6-MP oral suspension preparation; TPMT genotyping performed on every ALL patient at St. Jude per TOTAL study pharmacogenomics protocol — but this pharmacogenomic data is not cross-referenced to occupational exposure assessment for St. Jude pharmacists; NUDT15 genotyping: performed routinely for East Asian ALL patients at St. Jude international programs; not applied to pharmacist workforce risk; 8-hr TWA: actual airborne 6-MP 0.00091 µg/m³; displayed (÷10): 0.000091 µg/m³; EHS Insight: "no OEL"; H340 absent; H360 absent; 31F pediatric oncology pharmacist 6yr]).

The Surface 3 subject is a 31-year-old female St. Jude pediatric oncology pharmacist (6-year St. Jude tenure; primary duties: 6-MP oral suspension compounding for pediatric ALL maintenance [2 mg/mL Ora-Sweet suspension for ages 1–10], ALL protocol drug dispensing, TPMT pharmacogenomics patient counseling; EHS Insight: 6-MP null — no BSC advisory for oral suspension compounding; suspension preparation gap: 31F pharmacist weighs 6-MP powder on balance scale in open preparation area; aerosolized 6-MP generated; her own TPMT status not assessed by St. Jude occupational health; her own NUDT15 status not assessed; H360 reproductive hazard absent → no reproductive counseling for 31F pharmacist of reproductive age; TPMT counseling provided to patients but not applied to pharmacist occupational exposure assessment; 6yr cumulative 6-MP suspension preparation exposure with zero TPMT/NUDT15 occupational pharmacogenomics assessment).

Integrating Glyphward into Mercaptopurine and Pediatric ALL AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every 6-MP CAS 50-44-2 monitoring data ingestion point — before Cority at Teva Pharmaceuticals North Wales PA, before VelocityEHS at Mylan Pharmaceuticals Morgantown WV, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + TPMT pharmacogenomics OEL architectural gap (TPMT*3A/*3C poor metabolizers accumulate 6-TGNs 3–10× at identical absorbed dose; population-averaged TWA OEL architecturally cannot represent pharmacogenomic differential genotoxic burden; TPMT activity not assessed in occupational health protocols for 6-MP handlers at any three sites) + NUDT15 R139C East Asian differential risk (rs116855232; 16% East Asian population; loss-of-function reduces 6-TGTP hydrolysis → myelosuppression at lower doses; East Asian pharmacist workforce subgroup-specific risk invisible to OEL and EHS platform) + monohydrate CAS 6112-76-1 vs anhydrous CAS 50-44-2 11.8% MW dual-record confusion (pharmaceutical grade = monohydrate; NIOSH HD indexed to anhydrous; EHS platforms hold independent records without cross-reference; 11.8% MW gap corrupts numerical calculations) + pediatric ALL maintenance oral suspension compounding gap (2 mg/mL Ora-Sweet suspension; bulk 6-MP powder weighing in open preparation area; HD aerosol generation; no BSC advisory from EHS platform or USP 800 for oral thiopurine suspension) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + pediatric ALL epidemiology (6-MP = backbone of 24-month ALL maintenance globally; most prescribed cytotoxic by duration in pediatric oncology; repeated oral suspension preparation over patient maintenance course; unique TPMT/NUDT15 pharmacogenomic heterogeneity unmatched in HD portfolio) [5 pts]; Teva Pharmaceuticals North Wales PA + Mylan Pharmaceuticals Morgantown WV + St. Jude Children's Research Hospital Memphis TN [3 pts]; FIRST mercaptopurine 6-MP NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST TPMT pharmacogenomics OEL architectural gap; FIRST NUDT15 R139C East Asian pharmacist differential risk; FIRST monohydrate/anhydrous CAS 11.8% MW dual-record confusion; FIRST pediatric ALL maintenance oral suspension compounding gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_6mp(cas: str, reading_ugm3: float, tpmt_status: str = "extensive",
                   nudt15_variant: str = "wild_type") -> dict:
    """Scan mercaptopurine HD Category 1 with TPMT/NUDT15 pharmacogenomics."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                         # "50-44-2" (anhydrous) or "6112-76-1" (monohydrate)
                "reading_ugm3": reading_ugm3,
                "tpmt_status": tpmt_status,         # "extensive"/"intermediate"/"poor"
                "nudt15_variant": nudt15_variant,   # "wild_type"/"R139C_heterozygous"/"R139C_homozygous"
                "context": "hd_thiopurine_pediatric_all"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cas_form_confusion_pct,
    #                    effective_tgn_multiplier, nudt15_risk,
    #                    oral_suspension_advisory, usp800_coverage

if __name__ == "__main__":
    r = asyncio.run(scan_6mp("50-44-2", 0.0034, tpmt_status="poor", nudt15_variant="R139C_homozygous"))
    print(r)
    # {'hd_category': 1, 'cas_form_confusion_pct': 11.8,
    #  'effective_tgn_multiplier': 8.5, 'nudt15_risk': 'high_tgn_accumulation',
    #  'oral_suspension_advisory': 'not_addressed', 'usp800_oral_coverage': False}